Embryo selection exposes transferability paradox

Commercial embryo‑selection companies now claim high accuracy for complex traits, but those predictions rely on polygenic scores that perform very differently across ancestries — creating a paradox where marketed benefits are real for some populations and misleading for others. That gap forces a choice: acknowledge ancestry‑linked limits (and unequal benefit) or obscure them and sell a one‑size product. — This matters because it ties a technical limitation (polygenic score transferability) to market claims and potential inequality, shaping debates over regulation, informed consent, and reproductive ethics.